Eli Lilly to build $4.5 billion research and ... - NBC New York
WEB21 hours ago · The investment seeks to build upon Lilly's success from Mounjaro and Zepbound, which are riding a wave of popularity in so-called GLP-1 drugs. Lilly has 11 obesity drugs in its pipeline and wants ...
New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The Food and Drug Administration on Tuesday approved a new drug for Alzheimer’s disease, the latest in a novel class of treatments that has been greeted with hope, disappointment and...
Drugmaker Lilly slates another $4.5B for manufacturing and drug ...
WEB17 hours ago · Those drugs have funneled fresh revenue to Lilly and prompted the company in August to push its annual forecast beyond Wall Street expectations. Lilly shares soared to a new all-time high of $972.53 later that month. Eli Lilly and Co. also said in September that it was spending $1 billion to expand manufacturing at a …
FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla | AP News
WEBJul 2, 2024 · The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai.
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug ... - CNN
WEBJun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early...
FDA approves donanemab, Eli Lilly’s treatment for early ... - CNN
WEBJul 2, 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to ...
WEBNov 8, 2023 · The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16...
News Release - Eli Lilly and Company
WEBMay 13, 2022 · FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 …
FDA approves Eli Lilly's Alzheimer's drug Kisunla - NBC News
WEBThe Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people...
News Release - Eli Lilly and Company
WEBNov 8, 2023 · News Release. FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems. Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose.